The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
HER2 in Breast Cancer: A Review and Update
Abstract
HER2 (human epidermal growth factor receptor 2) receptor is a membrane tyrosine kinase and when activated affects cell proliferation and survival. The HER2 oncogene is located on chromosome 17q12. HER2 amplification is the primary pathway of HER2 receptor overexpression and is a major driver of tumor development and progression in a subset of breast cancers. HER2 is amplified in about 15% to 20% of breast cancers. The overexpressed HER2 receptor is a valuable therapeutic target. The 2007 ASCO guidelines mandate that HER2 should be evaluated in every invasive breast cancer, either at the time of diagnosis or recurrence to guide therapy. Currently HER2 testing is carried out by several methods. It is crucial to standardize testing techniques to accurately assess HER2 status. The aim of this review on HER2 in breast cancer is to discuss the important aspects of HER2 biology, its significance in breast cancer, and the current standards for its detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
HER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Whole Cancer Genome Sequencing by Next-Generation Methods
Ross, J. S., & Cronin, M. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpr1svt1vhugxw · Cited by 164
Hanna, W. M., & Kwok, K. (2006) · Modern Pathology · doi:10.1038/modpathol.3800555 · Cited by 110
Systematic Review of HER2 Breast Cancer Testing
Cuadros, M., & Villegas, R. (2008) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318169fc1c · Cited by 84
HER2 breast cancer therapies: a review
Modi, S., & Murphy, C. G. (2009) · Biologics · doi:10.2147/btt.2009.3250 · Cited by 69
Testing for HER2 in Breast Cancer: A Continuing Evolution
Shah, S., & Chen, B. (2010) · Pathology Research International · doi:10.4061/2011/903202 · Cited by 68
Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer
Viale, G. (2009) · The Journal of Pathology · doi:10.1002/path.2593 · Cited by 49
Cited by
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer
Kumar, N., Gulati, H. K., Sharma, A., Heer, S., Jassal, A. K., Arora, L., Kaur, S., Singh, A., Bhagat, K., Kaur, A., et al. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10133-y · Cited by 37
Heublein, S., Mayr, D., Egger, M., Karsten, U., Goletz, S., Angele, M., Gallwas, J., Jeschke, U., & Ditsch, N. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0152-7 · Cited by 18
Metadata
- Authors
- Krishnamurti, U., & Silverman, J. F.
- Venue
- Advances in Anatomic Pathology
- Published
- 2014-03
- Volume
- 21
- Issue
- 2
- Pages
- 100-107
- ISSN
- 1072-4109 (ISSN-L)
- OpenAlex
- W2324898974
- Cited by
- 328
- References
- 11
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER2 in Breast Cancer: A Review and Update. https://app.cochat.ai/papers/10.1097/pap.0000000000000015
- The paper
- Krishnamurti, U., & Silverman, J. F. (2014). HER2 in Breast Cancer: A Review and Update. Advances in Anatomic Pathology. https://doi.org/10.1097/pap.0000000000000015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
